Bortezomib for antibody-mediated rejection of kidney transplant in youth: Associations with donor-specific antibody.

Bortezomib was well tolerated and resulted in improvements in MFI of DSA among four pediatric subjects without allograft failure, although no effects were observed on eGFR trajectory. Further studies are needed to clarify whether earlier intervention with bortezomib could prevent renal failure progression.